What is the most recent earnings date for RLYB stock?
RALLYBIO CORP (RLYB) last reported earnings on 3/16/2026.
NASDAQ:RLYB • US75120L2097
Past quarterly earnings results for RALLYBIO CORP (RLYB), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -1.03 | -1.20 | 13.94% | 48.50% | 222K | 135.997K | 63.24% | 484.21% |
| Q3 2025 | -1.12 | -1.75 | 35.96% | 46.15% | 212K | 68.003K | 211.75% | -29.10% |
| Q2 2025 | -1.76 | -2.00 | 11.96% | 40.54% | 212K | - | -29.10% | |
| Q1 2025 | -1.68 | -2.12 | 20.81% | 55.32% | 212K | - | - | |
| Q4 2024 | -2.00 | -2.34 | 14.53% | 50.00% | 38K | 76.5K | -50.33% | - |
| Q3 2024 | -2.08 | -2.88 | 27.67% | 42.22% | 299K | - | - | |
| Q2 2024 | -2.96 | -3.05 | 3.01% | 19.57% | 299K | - | - | |
| Q1 2024 | -3.76 | -3.87 | 2.79% | -9.30% | - | - | ||
| Q4 2023 | -4.00 | -3.67 | -9.05% | -8.70% | - | - | ||
| Q3 2023 | -3.60 | -4.15 | 13.25% | 25.00% | - | - | ||
| Q2 2023 | -3.68 | -3.90 | 5.62% | 19.30% | - | - | ||
| Q1 2023 | -3.44 | -3.96 | 13.21% | 10.42% | - | - | ||
| Q4 2022 | -3.68 | -4.86 | 24.33% | -9.52% | - | - | ||
| Q3 2022 | -4.80 | -4.43 | -8.43% | -62.16% | - | - | ||
| Q2 2022 | -4.56 | -4.86 | 6.08% | 79.64% | - | - | ||
| Q1 2022 | -3.84 | -3.69 | -4.00% | - | - | - | ||
| Q4 2021 | -3.36 | -3.18 | -5.58% | - | - | - | ||
| Q3 2021 | -2.96 | -7.22 | 59.01% | - | - | - | ||
| Q2 2021 | -22.40 | -22.85 | 1.96% | - | - | - | ||
| Q1 2021 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - |
Notes
RALLYBIO CORP (RLYB) last reported earnings on 3/16/2026.
RALLYBIO CORP (RLYB) beat EPS estimates and beat revenue estimates in the most recent quarter.
In the last 4 quarters, RALLYBIO CORP (RLYB) has beaten EPS estimates in 4 out of 4 releases.